Please assess the completion status of the following clinical trial:

Trial Title: Treatment of RLS/WED Symptoms Through Sensory Counter-stimulation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients age 18 and over diagnosed with RLS/WED by a board certified sleep medicine physician within the Mayo Clinic Center for Sleep Medicine.~* Patients must have moderate to severe symptoms which have been present for ≥ 3 months. Patients must endorse discomfort as part of their typical RLS/WED symptomatology.~* Patients must experience daily symptoms and must experience daily symptoms during afternoon hours (12-5 PM)~* Patients on no medications for RLS/WED, or those who have refractory symptoms despite RLS/WED medications will be enrolled. Patients on alpha-2-delta ligands (pregabalin, gabapentin) will be asked to discontinue these medications two weeks prior to starting treatments and remain off these medications throughout the study protocol.~* Informed consent to participate in this study needs to be obtained~Exclusion Criteria:~* Research authorization not provided~* Patients who are asymptomatic (either by verbal report or completion of severity scale) at time of initiation of Scrambler Therapy treatment~* Patients who have made changes in medication regimen during the 2 weeks prior to study initiation (including initiation of iron supplementation)~* Prior use of Scrambler Therapy~* Pregnant or Nursing Patients~* Patients with implantable drug delivery systems, heart stents, or metal implants (including pacemakers and defibrillators)~* Patients with history of epilepsy or other medical conditions that in the opinion of the investigators should be excluded~* Patients with skin conditions or wounds in or around the area of electrode application (lower extremities)~* Patients treated with alpha-2 delta ligands (gabapentin, pregabalin), who cannot discontinue the medications as above

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Scrambler (Type: EXPERIMENTAL): All participants will receive electrical stimulation applied to the lower extremities using the Scrambler.

Based on this trial design, predict the completion outcome and termination type (if applicable).